SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

Investors are expressing widespread skepticism and frustration as the newly launched meme coin experienced a rapid and severe value decline, with many in the community labeling the movement as a "rug pull" and a scam. Traders are actively debating the token's lack of utility, comparing it to other politically-themed cryptocurrencies, and sharing reports of significant financial losses following its launch.

Talon Metals Corp. engages in the exploration and development of mineral properties. It holds interests in the Tamarack nickel-copper-cobalt and Trairão iron projects. The company was founded on April 5, 2005 and is headquartered in Road Town, British Virgin Islands.

Talon Metals Corp

Talon Metals is trending following the publication of the Tamarack mining project environmental review, which has triggered the public comment period and generated significant community discussion. Traders are closely monitoring this permitting milestone as a potential catalyst for further price appreciation.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Investors are closely watching the decision by Oracle Executive Chairman Larry Ellison to cancel his previously announced trading plan to sell up to 50 million shares. While some traders view the move as a major bullish signal that could trigger a short squeeze, others remain skeptical, pointing to the company's significant debt load, high capital expenditures, and ongoing AI market volatility.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors focus on upcoming clinical data catalysts, specifically the HARMONi-3 trial, and the November PDUFA date for ivonescimab. Community discussion is heavily driven by recent large-scale insider buying by management and speculation regarding the company's potential as a buyout target for major pharmaceutical firms seeking to address future patent cliffs.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending following a volatile earnings reaction where investors weighed strong order volume growth against concerns regarding future profit margins and ongoing investment spending. While some traders view the stock as a growth leader, others are skeptical of its high valuation and the sustainability of delivery margins in a competitive market.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending following its fiscal fourth-quarter earnings report and the return of founder Thomas Siebel as CEO, who underscored his commitment to the firm with a multimillion-dollar personal stock purchase. While community discussion is heavily focused on the stock's significant short interest and the potential for a short squeeze, traders remain divided over the company's long-term financial turnaround and operational execution.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is experiencing heightened attention driven by investor anticipation surrounding federal marijuana rescheduling and the company's solid operational performance, including recent share buybacks and revenue growth. While bullish sentiment centers on the company's strong balance sheet and potential for future uplisting, some traders express frustration regarding persistent stock price volatility and the slow pace of broader regulatory reform.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as investors react to the company's recent capital raise and potential legal catalysts, specifically upcoming court hearings regarding the restart of its Santa Ynez pipeline system. While community sentiment is divided between optimism over the company's long-term production potential and concerns regarding dilution and regulatory hurdles, many traders are focusing on the stock's significant short interest and the potential for a rebound following the recent financing news.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is experiencing heightened community interest driven by anticipation of upcoming partnership announcements and the integration of institutional-grade payment rails, with many traders accumulating tokens while expressing frustration over recent price volatility. While some participants are optimistic about the project's long-term potential and real-world utility, others remain skeptical, dismissing the movement as speculative or labeling the asset as a pump-and-dump scheme.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero is trending due to its recent Q2 earnings beat, which exceeded analyst expectations for EPS and revenue, while community discussion continues to monitor the impact of California regulatory pressure on the company's regional refinery operations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

As my recent$ARGX play was successful I will share my current largest bets for 2026:

$CLDX Phase 3 CSU, KIT antibody, Sept/Oct.
$BHVN Phase 2/3 epilepsy, Kv7.2/7.3 ion channel small molecule activator + phase 2 muscle-sparing obesity, myostatin-binding human recombinant protein, both readouts expected in second half of 2026. Lowest confidence readout for a variety of reasons.
$SYRE Phase 2 RA, YTE TL1A antibody, Sept. SKYLINE UC IL-23 mono arm coming in as well. The major play here for me is the 2027 SKYLINE combos.
$CLYM Phase 2 pMN, 1b SLE and additional 1b results for ITP, CD19 antibody, Q4.
$PTGX FDA approval for Rusfertide expected in August but this may be priced in. Long-term diamond hands hold for me either way.

Also maintaining a small position in Argenx for their Q4 readout and Abivax for their MiR-124-enhancing drug Q4 FDA submission. I think the FDA could really do Abivax dirty though and slap a black box warning on obefazimod so I am cautious on this one.

StockTwits for iOS

Celldex Therapeutics Inc.

Biohaven Pharmaceutical Holding Company Ltd

Spyre Therapeutics Inc

Climb Bio Inc.

Protagonist Therapeutics Inc

As my recent$ARGX play was successful I will share my current largest bets for 2026:



 Phase 2/3 epilepsy, Kv7.2/7.3 ion channel small molecule activator + phase 2 muscle-sparing obesity, myostatin-binding human recombinant protein, both readouts expected in second half of 2026. Lowest confidence readout for a variety of reasons.


 Phase 2 RA, YTE TL1A antibody, Sept. SKYLINE UC IL-23 mono arm coming in as well. The major play here for me is the 2027 SKYLINE combos.


 Phase 2 pMN, 1b SLE and additional 1b results for ITP, CD19 antibody, Q4.


 FDA approval for Rusfertide expected in August but this may be priced in. Long-term diamond hands hold for me either way.

Also maintaining a small position in Argenx for their Q4 readout and Abivax for their MiR-124-enhancing drug Q4 FDA submission. I think the FDA could really do Abivax dirty though and slap a black box warning on obefazimod so I am cautious on this one.